– Merger to create NASDAQ-listed, commercial-stage AI-Enabled medical technology company focused on bringing FDA-cleared Brain Network Analytics platform to NASDAQ Capital Markets FAIRFAX, Va., Nov… Read More »WaveDancer Announces Merger Agreement with Firefly Neuroscience
Overview Novartis, a global leader in healthcare innovation, recently embarked on a groundbreaking study introducing MIJ821 (onfasprodil), a novel therapeutic candidate for the treatment of… Read More »Novartis leveraged BNA™ technology for its first in-human study on an innovative antidepressant
Real-life data analysis conducted with a large multi-specialty health and psychiatry clinic in the US. Data was collected from 2,253 patients who visited a psychiatric… Read More »Brain Network Analytics (BNA™) in the Psychiatric Practice
Firefly Neuroscience is thrilled to share the publication of the Bright Minds Biosciences Inc., a biotechnology company, first in-human Phase 1 study of its lead… Read More »BNA™ supports Bright Minds Biosciences with qEEG Data from its First in-Human Phase 1 Study of Lead Compound, BMB-101
Transcranial magnetic stimulation (TMS) is an effective intervention approach for patients with psychiatric disorders such as major depressive disorder (MDD) and general anxiety disorder (GAD).… Read More »Personalizing TMS Protocols with BNA™: A Case Study Demonstrating Improved Outcomes
The future of brain healthcare is brighter than ever thanks to the improved ability to analyze high-quality EEG data with state-of-the-art AI Applying our AI… Read More »The Future of Brain Healthcare is Brighter Than Ever with State-of-the-Art AI
One pivotal area where AI is making a remarkable impact is in the analysis and interpretation of electroencephalography (EEG)
The combination of STALICLA and Firefly Neuroscience’s machine learning platforms and know-how will further strengthen the development of precision medicine for these patients Geneva, Switzerland… Read More »STALICLA and Firefly Neuroscience enter Partnership Agreement for the development of Electroencephalogram (EEG) as Biomarker for Subgroups of Patients with ASD
We were fortunate to have the opportunity to sit down with Dr. Raul Rodriguez of Delray Center for Brain Science (Founder & Medical Director) who… Read More »Making Brain Activity Tangible
Mild cognitive impairment (MCI) defines the intermediate state between healthy cognition and early dementia1 and is not typical for normal brain aging2. In 2020 the… Read More »Screening & Managing MCI (Mild Cognitive Impairment)
Chief Financial Officer
Chairman
Chief Marketing Officer
Chief Executive Officer
